Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pCMFlag_hsMAFG (#RDB06413)

Expression vector of human MAFG.

Alternative name SET-0065_6
Clone info. Expression vector of human MAFG. Expression was confirmed by Western blotting with anti-FLAG antibody.
Comment Derived from Sugano BC012327. PCR cloning, forward primer: ATGACGACCCCCAATAAAGG; reverse primer: CTACGATCGGGCATCCGTCT.
Vector backbone pCMV_S-FLAG (RDB05956) (Plasmid)
Size of vector backbone 5.5 kb
Selectable markers Amp^r (E. coli), Neo^r (mammalian cell)
Growth conditions 37C, LB+Amp
Gene/insert name Human MAFG cDNA
Depositor|Developer DNA Bank, |
 
Remarks, protocol and/or map (pdf) RDB06413.pdf

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL and cite Gene 200, 149-156, 1997 in any publication.
Additional terms and conditions:
Regrding pRc/CMV:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
提供同意書 (MTA, 営利目的用)[Word]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 発表に際し、理研BRCから入手したことを明記し、指定する文献(Gene, 200, 149-156 (1997))を引用すること。
付加的使用条件:
pRc/CMVについて:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.

Catalog # Resource name Shipping form Fee
RDB06413 pCMFlag_hsMAFG DNA solution JPY 9,460 (not-for-profit academic purpose)
JPY 18,920 (for-profit-research purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pCMFlag_hsMAFG was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB06413).

Reference section:

Further references such as user reports and related articles (go to bottom)


QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB13708_A5Kap1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: CMV-Forward
Sequence file: RDB13708_A5Kaa.seq check
>06413_13708_A5Ka_CMV-Forward_A05_02.ab1
    1 ATTAACTCGC CCATTGACGC AATGGGCGGT AGGCGTGTAC GGTGGGAGGT CTATATAAGC
   61 AGAGCTCTCT GGCTAACTAG AGAACCCACT GCTTACTGGC TTATCGAAAT TAATACGACT
  121 CACTATAGGG AGACCCAAGC TGAATTCACC ATGGACTACA AGGACGATGA CGATAAGGCG
  181 GCCATGACGA CCCCCAATAA AGGAAACAAG GCCTTGAAGG TGAAGCGGGA GCCGGGTGAG
  241 AATGGCACCA GCCTGACGGA TGAGGAGCTG GTGACCATGT CGGTGCGGGA GCTGAACCAG
  301 CACCTGCGGG GCCTGTCCAA GGAGGAGATC GTCCAGCTGA AGCAGCGCCG GCGCACGCTC
  361 AAGAACCGCG GCTACGCTGC CAGCTGCCGC GTGAAGCGGG TGACGCAGAA GGAGGAGCTG
  421 GAGAAGCAGA AGGCGGAGCT GCAGCAGGAG GTGGAGAAGC TGGCCTCAGA GAACGCCAGC
  481 ATGAAGCTGG AGCTCGACGC GCTGCGCTCC AAGTACGAGG CGCTGCAGAC CTTCGCCCGG
  541 ACGGTGGCCC GCAGCCCCGT GGCGCCAGCC CGGGGCCCCC TTGCCGCCGG CCTGGGGCCC
  601 CTCGTCCCAG GCAAGGTGGC CGCCACCAGC GTCATCACAA TAGTAAAGTC CAAGACGGAT
  661 GCCCGATCGT AGGGCCGCTC GAGCATGCAT CTAGAGGGCC CTATTCTATA GTGTCACCTA
  721 AATGCTAGAG CTCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT
  781 TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAGGTGCCA CTCCCACTGT CCTTTCCTAA
  841 TAAAATGAGG AAATTGCATC GCATTGTCTG AGTATGTGTC ATTCTATTCT GGGGTGTGGT
  901 TTAGCCAGGA CAGCAAGGGG GGGGAGGGAT TGGGAAGACC ATAGCAGGGC ATGCTGGGGA
  961 ATGCGTGGGC TCTATGGCTT CCTGAGGCGG AAGAACCTAG CTGGAGCTCG AAGGGGAATC
1021 GCCACGTCGC CTGTAGCGGC CGCATT
//
Primer: SV40pro_F_V2
Sequence file: RDB13708_A5Kab.seq check
>06413_13708_A5Ka_SV40pro_F_V2_B05_05.ab1
    1 GGGGACGTTT TGGAGCTAGG CTTTTGCAAA AGCTCCCGGG AGCTTGGATA TCCATTTTCG
   61 GATCTGATCA AGAGACAGGA TGAGGATCGT TTCGCATGAT TGAACAAGAT GGATTGCACG
  121 CAGGTTCTCC GGCCGCTTGG GTGGAGAGGC TATTCGGCTA TGACTGGGCA CAACAGACAA
  181 TCGGCTGCTC TGATGCCGCC GTGTTCCGGC TGTCAGCGCA GGGGCGCCCG GTTCTTTTTG
  241 TCAAGACCGA CCTGTCCGGT GCCCTGAATG AACTGCAGGA CGAGGCAGCG CGGCTATCGT
  301 GGCTGGCCAC GACGGGCGTT CCTTGCGCAG CTGTGCTCGA CGTTGTCACT GAAGCGGGAA
  361 GGGACTGGCT GCTATTGGGC GAAGTGCCGG GGCAGGATCT CCTGTCATCT CACCTTGCTC
  421 CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG GCTGCATACG CTTGATCCGG
  481 CTACCTGCCC ATTCGACCAC CAAGCGAAAC ATCGCATCGA GCGAGCACGT ACTCGGATGG
  541 AAGCCGGTCT TGTCGATCAG GATGATCTGG ACGAAGAGCA TCAGGGGCTC GCGCCAGCCG
  601 AACTGTTCGC CAGGCTCAAG GCGCGCATGC CCGACGGCGA GGATCTCGTC GTGACCCATG
  661 GCGATGCCTG CTTGCCGAAT ATCATGGTGG AAAATGGCCG CTTTTCTGGA TTCATCGACT
  721 GTGGCCGGCT GGGTGTGGCG GACCGCTATC AGGACATAGC GTTGGCTACC CGTGATATTG
  781 CTGAAGAGCT TGGCGGCGAA TGGGCTGACC GCTTCCTCGT GCTTTACGGT ATCGCCGCTC
  841 CCGATTCGCA GCGCATCGCC TTCTATCGCC TTCTTGACGA GTTCTTCTGA GCGGGACTCT
  901 GGGGGTTCGA AATGACCGAC CAAGCGACGC CCAACCTGCC ATCACGAGAT TTCGATTCCA
  961 CCGCCGCCCT TCTATGAAGG GTTTGGGGCT TCGGAATCGT TTTCCCGGGG ACGCCCGGCT
 1021 GGATTGATTC CTTCCAGCGG CGGGGATCTC AATGCTGGGA AGTCCATCGG CCCAACCCCA
1081 ACTTGTTTTA TTTGCCAGGC GCCAG
//

Please visit Sequencing and PCR primers for primer information.


References

Original, user report and related articles